| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Unregistered Sales of Equity Securities
As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) entered into an Advisory Agreement (the “Advisory Agreement”) with Green Dragon Investments LLC (“Green Dragon”), pursuant to which the Company agreed to pay G... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred |
| 24 Jul 2026 |
8-K: Regulation FD Disclosure
INVESTOR PRESENTATION The largest public equity vehicle built to provide accessibility to Litecoin July 2026 Nasdaq: LITS |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, CA, May 13, 2026 – Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the f... |
| 17 Feb 2026 |
8-K: Results of Operations and Financial Condition
Second Quarter Performance Driven by Successful Deployment of Treasury Operations; Reflecting Commitment to Strategic Focus on Leveraging Litecoin Holdings Complemented by Disciplined Capital Allocation |
| 12 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The Lite Strategy, Inc. 2026 Stock Omnibus Equity Compensation Plan (as amended from time to time, the “Plan”), maintained by Lite Strategy, Inc. authorizes the Compensation Committee to provide grants of equity compensation to Advisors,... |
| 30 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
9920 Pacific Heights Blvd., Suite 150San Diego, CA 92121(858) 369-7100 |
| 05 Dec 2025 |
8-K: Changes in Registrant's Certifying Accountant
December 5, 2025Securities and Exchange Commission100 F Street, N.E.Washington, D.C. 20549-7561 |
| 18 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
As previously disclosed on the Current Report on Form 8-K filed with the SEC on July 22, 2024, the Board of Directors (the Board) of Lite Strategy, Inc. (the Company) previously appointed Justin J. File as the Acting Chief Executive Offi... |
| 30 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Lite Strategy Announces $25M Share Repurchase Program, Signalling Shift From Initial Litecoin Accumulation to Active Capital Market Operations |
| 15 Sep 2025 |
8-K: Unregistered Sales of Equity Securities
As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 6,022,869 shares of the Company’s Common Stock, par value $0.00000002 ... |
| 10 Sep 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’ |
| 04 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This Master Loan Agreement (the “Agreement”) is dated as of 3rd of September, 2025 by and between BitGo Prime, LLC (“BitGo,” “BitGo Prime,” or “Lender”), a limited liability company organized and existing under the laws of Delaware, and ... |
| 06 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 5, 2025, Steven D. Wood informed the board of directors (the “Board”) of MEI Pharma, Inc. (the “Company”) of his decision to resign as a director of the Company, effective immediately. Mr. Wood’s decision to resign from the Boa... |
| 05 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
SAN DIEGO, 5 August 2025 – MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury st... |
| 30 Jul 2025 |
8-K: Unregistered Sales of Equity Securities
As previously reported, on July 22, 2025, the Company issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 6,022,869 shares of the Company’s Common Stock, par value $0.00000002 per share (the “Common S... |
| 22 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
MEI Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Titan Partners Group LLC, a division of American Capital Partners, L... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO--(BUSINESS WIRE) — May 13, 2025 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. |
| 07 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
11455 El Camino Real, Suite 250San Diego, CA 92130(858) 369-7100 |
| 12 Feb 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO--(BUSINESS WIRE) — February 12, 2025 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. |
Loading...